Mode
Text Size
Log in / Sign up
N/A Completed N=4,748

Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647)

Source: ClinicalTrials.gov NCT00909389 ↗
Enrolled (actual)
4,748
Serious AEs
0.1%
Results posted
Oct 2011
Primary outcomePrimary: Number of Participants Who Had an Adverse Event (AE). — 62 participants

Summary

This study aims to establish the safety, tolerability, and efficacy of Vytorin (R) (Ezetimibe + Simvastatin) (SCH 465981) on a select population of Filipinos with hypercholesterolemia.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants Who Had an Adverse Event (AE).
62 —

Eligibility Criteria

Inclusion Criteria

  • Outpatient men or women, age 18 years and above
  • Patients with primary (heterozygous familial and non-familial) hypercholesterolemia

Exclusion Criteria

  • Known hypersensitivity to Ezetimibe and Simvastatin
  • Moderate to severe hepatic insufficiency
  • Persistent elevation of serum transaminase levels of more than 1.5 times the upper limit of normal
  • Pregnancy or lactation
  • Concomitant intake of bile acid sequestrants (resins), nicotinic acid (niacin), fibric acid (fibrates), or cyclosporine
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00909389). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search